Drug intelligence / Profile preview

Lepijet

Development stage: Unknown
Lead developer: Bio-STILOGIT Pharmaceuticals
Modality: Small Molecules
Administration: Oral

Overview

Lepijet is a multi-ingredient dietary supplement developed by Bio-STILOGIT Pharmaceuticals, specifically formulated to support male fertility and reproductive health. The product contains a blend of L-carnitine, acetyl-L-carnitine, coenzyme Q10, zinc, folic acid, vitamin B12, and selenium. These components work synergistically to improve sperm quality by enhancing mitochondrial energy metabolism and providing antioxidant defense against oxidative stress, which can otherwise lead to sperm DNA fragmentation and reduced motility. Lepijet is marketed as a retail consumer product in Italy, primarily for the management of male factor infertility and the optimization of reproductive parameters.

Brand names: Lepijet

Targets

DNAND1 (Mitochondrial electron transport chain complex I)

Beyond the preview

Go deeper on Lepijet.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lepijet.

Explore the full profile